drugset
Drugs / MPD-1
last change Dec 2024 re-read 3 minutes ago

MPD-1

Developed for
cancer
Investigated by
Pharosgen Co.,Ltd

Trials 1

today NCT06944457 · Ph 1
202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06944457 Dec 2024 → Dec 2026 expected cancer Pharosgen Co.,Ltd Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 3

DateIssuerRelease
2024-11-11 Beyond Air Inc. Results Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting beyondair.net ↗
Additionally, LV UNO was shown to be more effective than High Volume UNO (HV UNO; 1 L) in reducing tumor volumes in CT26 BALB/c mice when paired with anti-mPD-1 treatment.
2023-10-17 Beyond Air Inc. Results Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice beyondair.net ↗
The combination of UNO and anti-mPD-1 resulted in a potent, synergistic immune response,
2023-10-16 Beyond Air Inc. Results Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics beyondair.net ↗
Pooled analysis of combination studies of 50,000 or 100,000 ppm UNO with anti-mPD-1 demonstrated more than a doubling in survival at Day 75 versus anti-mPD-1 alone

All press releases naming this drug 3 releases

DateIssuerRelease

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MPD-1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06944457 ↗